3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
3
Colorectal Neoplasms
2
Thyroid Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
EGFR-mutant Non-small Cell Lung Cancer
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
244
Carboplatin
214
Pemetrexed
180
Cisplatin
134
Paclitaxel
115
Nivolumab
102
Docetaxel
88
osimertinib
85
durvalumab
79
Specimen Handling
56
atezolizumab
55
Gemcitabine
53
Drug Therapy
53
Magnetic Resonance Spectroscopy
50
Radiosurgery
49
Radiotherapy
48
Ipilimumab
41
130-nm albumin-bound paclitaxel
39
cemiplimab
38
Bevacizumab
35
tislelizumab
31
Cetuximab
30
amivantamab
23
Taxes
22
Blood Specimen Collection
21
Platinum Compounds
20
Immunotherapy
18
Immune Checkpoint Inhibitors
18
Radiation
17
Erlotinib Hydrochloride
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
naporafenib
×
1 year
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled